BioSpace News Archive

Pyxis Oncology, Inc. reported on December 23, 2022 that Pyxis Oncology’s Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 52,560 shares of Pyxis Oncology’s common stock and stock options to purchase an aggregate of 65,701 shares of Pyxis Oncology’s common stock to five newly hired employees.

Ardelyx, Inc. announced that on December 16, 2022, the compensation committee of the company’s board of directors granted 17 new non-executive employees options to purchase an aggregate of 271,735 shares of the company’s common stock, and an aggregate of 123,375 Restricted Stock Units.

Metacrine, Inc. and Equillium, Inc. announced the mutual termination of their previously announced definitive merger agreement.

The U.S. Food and Drug Administration issued a Complete Response Letter regarding the New Drug Application for palovarotene, an investigational treatment for the reduction of new abnormal bone formation in people living with fibrodysplasia ossificans progressiva.

Hyphens Pharma International Limited is pleased to announce that its subsidiary, Hyphens Pharma Pte. Ltd., has entered into exclusive license and supply agreements with Cassiopea S.p.A., a subsidiary of Cosmo Pharmaceuticals N.V. for the exclusive rights to develop and commercialize Winlevi® cream 1% and all future product extension and/or improvement in the treatment of acne in 10 countries across Southeast Asia.

Immuron receives U.S. Food and Drug administration (FDA) approval for Travelan Investigational New Drug (IND) application.

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today shared multiple accomplishments and advances in its research and development (R&D) programs.

Equillium, Inc. and Metacrine, Inc. announced the mutual termination of their previously announced definitive merger agreement.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 11,250 shares of the Company’s common stock at an exercise price per share of $20.41, which was the closing price on December 23, 2022, and restricted stock units to acquire a total of 5,625 shares of the Company’s common stock.